NCT05662852View on ClinicalTrials.gov

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions
Tetanus, Diphtheria and Acellular Pertussis Vaccination
Interventions
BIOLOGICAL

Tdap

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur

Trial Locations (1)

08028

ABO Plasma, Glassboro

All Listed Sponsors
lead

ABO Holdings, Inc.

INDUSTRY

NCT05662852 - Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors | Biotech Hunter | Biotech Hunter